2025年上半年，国货美妆上市公司整体业绩表现亮眼。从发展策略来看，各企业思路较为相似，主要集 中在推动核心品牌建设、发力电商渠道营销以及持续孵化新产品线，共同拉动收入与利润双增长。 具体来看，上海家化上半年实现营收34.8亿元，同比增长4.7%；归母净利润2.7亿元，同比增长11.7%。 公司持续推进核心品牌战略与线上渠道建设，旗下六神、玉泽等品牌通过产品线拓展实现显著增长。 丸美生物同期实现营收17.69亿元，同比增长30.83%；归母净利润1.86亿元，同比增长5.21%。报告期 内，丸美深化大单品策略，构建大单品矩阵；丸美与PL恋火双品牌市场渗透率不断提升。 21世纪经济报道记者翁榕涛 实习生赖桂筠、吴梓轩 国货美妆正步入发展深水区。 近日，包括上海家化（600315.SH）、丸美生物（603983.SH）、上美股份（02145.HK）等国货美妆上 市公司纷纷披露2025年半年报或者盈利预告，从财报数据来看，行业业绩呈现明显分化，反映市场竞争 已从早期的渠道扩张，转向研发创新与精准化布局的科技较量。 从竞争格局来看，尽管全球市场上流行的功能性护肤品品牌基本被欧莱雅、资生堂、雅诗兰黛等欧洲、 日本和美国 ...

分析人士认为，或许因为当年大热的伊蒂之屋、悦诗风吟在中国市场的势头已大不如前，爱茉莉太平洋 开始引入新品牌来增强自己在中国市场的声量。 相较于其他的国际美妆巨头，爱茉莉太平洋近些年在中国市场较为"沉寂"，鲜有新的大动作。但近期记 者注意到该公司将旗下护肤品牌AESTURA瑷丝特兰（下称"瑷丝特兰"）引入中国市场。 公司方面向记者表示，瑷丝特兰主打敏感肌细分类市场。目前品牌在中国市场的规划以线上销售为主。 在2025年11月的中国国际进口博览会中，瑷丝特兰将随集团参展，首次线下亮相。 近年来，中国敏感肌肤人群护肤需求旺盛，敏感肌护肤这样的细分类市场热度不断攀升，越来越多的品 牌开始加码这一赛道。 根据今年5月发布的一季报，爱茉莉太平洋集团录得合并销售额1.16万亿韩元，同比增长15.7%；营业利 润达1289亿韩元，同比增长高达55.2%。其中，海外业务销售同比增长40.5%，达到4730亿韩元；营业 利润则增长120.5%。由此可见，对于集团来说，包括中国市场在内的海外业务是其未来增长的重要板 块之一。 爱茉莉太平洋中国去年经历了高层的变动调整。2024年4月，爱茉莉太平洋集团任命朴泰镐（Taeho Park ...

Core Insights - The Watsons Health and Beauty Awards (HWB) 2025 announced that Winona won the Best Brand Award and its Clear Sunscreen won the Best Product Award, marking a significant achievement for the brand in the sensitive skin care market [1][3] Group 1: Brand Performance - Winona has maintained its position as the number one brand in sensitive skin care sales in China from 2020 to 2024, as certified by international agency, Sullivan [2][3] - The brand's success is attributed to its unique approach of developing skin care products based on clinical research and consumer needs, establishing a strong reputation and trust among consumers [2][4] Group 2: Product Innovation - Winona's new generation of star product, the second-generation Winona Special Care Cream, represents a significant iteration after 13 years, utilizing breakthrough technology for effective skin repair [3][4] - The Clear Sunscreen, which has been on the market for ten years, is recognized for its gentle formulation and effectiveness, having been rigorously tested for safety and efficacy [4][5] Group 3: Market Strategy - Winona's "Sensitive Skin PLUS" strategy focuses on addressing specific needs within the sensitive skin demographic, creating a diverse product line that includes specialized creams and sunscreens [4][5] - The brand has achieved significant recognition in the market, ranking in the top 10 sales at Watsons and demonstrating strong consumer approval [3][5] Group 4: Future Outlook - Winona aims to lead the sensitive skin care sector with medical-grade standards, continuously enhancing consumer trust and satisfaction while striving for health and beauty goals [7]

Core Viewpoint - Beitaini's revenue and net profit have significantly declined in recent quarters, indicating pressure on its financial performance and the need for strategic adjustments in its product offerings and market positioning [3][5][6]. Financial Performance - In 2024, Beitaini's revenue growth rates were 3.87% and -13.51% for the first quarter, while net profit growth rates were -33.53% and -83.97% respectively [3][5]. - The company's net profit for 2024 dropped to 503 million yuan, less than half of the same period in 2022 [6]. - The overall performance in the first quarter of 2025 showed a revenue of 949 million yuan, a decline of 13.51%, and a net profit of 28 million yuan, marking an 84% decrease, the lowest since its listing [7]. Brand and Product Strategy - Beitaini focuses on the "skin health internet+" model, with multiple brands including Winona, Winona Baby, and AOXMED, targeting various skincare needs [5]. - The main brand, Winona, has undergone a brand upgrade to focus on "sensitive skin," launching key products like the Winona Soothing Moisturizing Cream [9]. - Despite the brand's efforts, Winona's revenue declined by 5.5% in 2024, contrasting with significant growth in its sub-brands Winona Baby and AOXMED, which saw increases of 34% and 65.6% respectively [9][10]. Market Position and Competition - Beitaini's performance in major promotional events has weakened, with Winona ranking 10th in the Tmall beauty sales during the 2024 promotional events, down from 5th in 2023 [9][11]. - The company faces increased competition and has had to raise marketing expenditures, impacting profitability [6][10]. Future Outlook - Beitaini plans to implement five core solutions for its main brand, focusing on enhancing customer value through product combinations [10]. - The company aims to leverage its advancements in plant-based ingredients and AI technology to regain market traction [9].

Financial Performance - In 2024, Betaini achieved operating revenue of 5.736 billion yuan, a year-on-year increase of 3.87% [1] - The company's operating cash flow has maintained positive growth for three consecutive years, with a year-on-year increase of 13.83% in 2024, indicating strong self-sustaining capabilities of its core business [1] - Betaini's cumulative cash dividends from 2021 to 2024 reached 1.098 billion yuan, accounting for 34.6% of net profit attributable to shareholders, with a proposed cash dividend of 253 million yuan in 2024, increasing the dividend payout ratio to 50.3% [1] Operational Management - Betaini has achieved significant results through continuous inventory optimization, leading to a sustained decline in inventory levels from 2023 to Q1 2025, which directly contributed to an increase in gross margin to 77.47% in Q1 2025 [1] Brand Development - Betaini is expanding its growth space by deepening its focus on sensitive skin, transitioning from a single product line to multi-functional and multi-scenario solutions [2] - The core brand Winona has launched new products targeting sensitive skin, including the Winona Silver Core Cream, which has entered the anti-aging segment for sensitive skin [3][5] - The sensitive skin market is large, with 42% of the Asian population reporting sensitive skin, and 54% globally, indicating a broad market for skincare needs [8] Research and Development - In 2024, Betaini's R&D expenditure reached 337 million yuan, accounting for 5.87% of total revenue, significantly higher than the average R&D ratio in the A-share beauty sector [13] - Betaini has established a comprehensive R&D system from plant selection to efficacy verification, successfully filing for 13 new cosmetic raw materials, leading in the domestic beauty industry [11] ESG Strategy - Betaini has integrated ESG strategies into its operations, establishing a green management system across the entire supply chain, leveraging the ecological advantages of Yunnan's "Plant Kingdom" [15] - The company has implemented various measures for energy conservation and emission reduction, including reducing plastic usage in packaging by 22 tons compared to 2023 [17] - Betaini has committed over 21.32 million yuan to social responsibility initiatives, including scholarships and support for vulnerable groups [17]

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company has released its 2024 annual report and Q1 2025 quarterly report, with performance slightly below market expectations. 2024 revenue was 5.736 billion yuan, a year-on-year increase of 3.87%, while net profit attributable to shareholders was 503 million yuan, a year-on-year decline of 33.53% [4][6] - In Q1 2025, revenue was 949 million yuan, a year-on-year decline of 13.51%, and net profit attributable to shareholders was 28 million yuan, a year-on-year decline of 83.97% [4][6] - The company plans to focus on brand building, member operations, and overall collaborative growth in 2025, with a strategic emphasis on sensitive skin products [6] Financial Data and Profit Forecast - The company’s total revenue for 2024 is projected at 5.736 billion yuan, with a forecasted revenue of 6.281 billion yuan for 2025, representing a year-on-year growth rate of 9.5% [5] - The net profit attributable to shareholders is expected to be 667 million yuan in 2025, with a projected growth rate of 32.6% [5] - The gross profit margin for 2024 was 73.7%, with an expected margin of 74.9% in 2025 [5] Operational Insights - The company’s skincare segment showed resilience despite pressure, with skincare revenue at 4.801 billion yuan in 2024, a year-on-year decline of 1.42% [6] - The makeup segment experienced significant growth, with revenue increasing by 226.51% to 551 million yuan, accounting for 9.60% of total revenue [6] - Online sales channels drove overall resilience, with revenue from online channels reaching 3.912 billion yuan, a year-on-year increase of 10.13% [6] Strategic Focus - The company is deepening its "Sensitive Skin PLUS" strategy, focusing on core products that enhance brand value and sales [6] - The brand matrix includes various sub-brands targeting specific demographics, such as infants and anti-aging products, to achieve precise market coverage [6] - The organizational restructuring is expected to bring positive changes, with a focus on high-end and mass-market segments [6]

Group 1 - The core viewpoint of the article highlights that Yunnan Betaini Biotechnology Group Co., Ltd. reported a revenue of 5.736 billion yuan for 2024, marking a year-on-year increase of 3.87%, while net profit decreased by 33.53% to 503 million yuan due to various factors including increased marketing expenses and rising operational costs [1][2] - The revenue growth is attributed to the company's continuous investment in brand expansion, product innovation, and channel development, alongside effective product strategies [1] - The company plans to distribute a cash dividend of 6 yuan per 10 shares, totaling 253 million yuan for its shareholders [1] Group 2 - In 2024, the company's R&D investment reached 337 million yuan, maintaining over 5% of revenue dedicated to R&D for three consecutive years, emphasizing its strategy of building value through technological barriers [1] - The company is focusing on a dual strategy of "multi-brand synergy + product matrix expansion" to enhance market vitality, particularly targeting sensitive skin consumers with core brand Winona consistently ranking in the top ten on Tmall for eight years [1] - The high-end anti-aging sub-brand AOXMED saw a revenue increase of 65.59% year-on-year in 2024, showcasing the effectiveness of the brand's collaborative efforts in niche markets [1][2] Group 3 - The Chinese dermatological skincare market is expanding, with a market size of approximately 33.96 billion yuan, growing by about 3.30% year-on-year despite a slowdown in overall cosmetics retail [2] - Analysts predict that domestic brands will continue to rise as international beauty brands retreat from the market, reinforcing confidence in domestic consumption and the growth of local brands [2] - The company is establishing a framework for sustainable growth amidst industry challenges, focusing on its mission to create a "Chinese skin health ecosystem" and enhancing its brand foundation and ecological layout [2]